ArticleHead and neck pathology2026
Circulating Tumor High Risk HPV DNA as the HPV-Specific Test in Oropharyngeal Squamous Cell Carcinoma Patients.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe uses for circulating tumor high risk human papillomavirus DNA (ctHPVDNA) in the diagnostic work-up and treatment of HPV-associated oropharyngeal squamous cell carcinoma (HPV( +)OPSCC) patients are actively being investigated. We evaluated the concordance of ctHPVDNA with tissue-based HPV testing (p16 immunohistochemistry (IHC), DNA in situ hybridization (ISH), and/or RNA ISH) to assess its performance as a primary diagnostic test for patients' HPV status.
methodsWe conducted a retrospective cross-sectional study of patients evaluated at a tertiary care multidisciplinary oropharyngeal cancer clinic with suspected HPV( +)OPSCC who underwent pre-treatment ctHPVDNA testing (HPV types 16, 18, 31, 33, 35) via the NavDx assay.
resultsOf 236 patients with OPSCC, 190 (81%) had a positive ctHPVDNA result. 41 (17%) were negative, and 3 (1%) were indeterminate. Of the 190 patients with a positive ctHPVDNA result, 190 (100%) had positive tissue-based HPV testing. Of the 41 patients with a negative result, 34 (83%) had positive tissue-based HPV testing and 7 (17%) were negative. ctHPVDNA demonstrated a sensitivity of 85% (95% CI 79-89%), specificity of 100% (95% CI 59-100%), NPV of 17% (95% CI: 7-32%), and PPV of 100% (95% CI 98-100%).
conclusionThe high specificity and PPV of ctHPVDNA indicate that in the setting of a positive result and high clinical suspicion, it may not be necessary for pathologists to test subsequent cytology or tissue specimens that are diagnostic for SCC for p16 or HPV. In the setting of a negative ctHPVDNA result, however, our findings indicate that HPV testing of a pathology specimen must still be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.